At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer
In Brief
A Phase 1 clinical trial evaluating CABOZANTINIB and gemcitabine for Pancreatic Cancer. Completed, enrolled 12 participants across 1 site.
Detailed Summary
Gemcitabine is considered one of the standard drugs for advanced pancreatic cancer and is approved by the FDA to treat it. Cabozantinib is a new drug that has demonstrated effectiveness against pancreatic cancer in laboratory experiments, especially when given with gemcitabine. Initial studies with cabozantinib in pancreatic cancer have shown some activity against the disease. The purpose of this study is to determine the safest and highest dose of cabozantinib that can be given together with standard doses of gemcitabine in patients with pancreatic cancer. This study will determine the safety and tolerability of this two drug combination.
Study Details
Timeline
Interventions
Daily oral cabozantinib administered days -7 until disease progression, intolerable adverse event(s) or patient choice.
Gemcitabine administered intravenously on days 1, 8, and 15 every 28 days.